ATEC Sees Growth, FPRX Gets High-Five, RNA Walks The Talk, RPRX On The Move

Acceleron Pharma Inc.'s (XLRN: Quote) collaboration partner, Celgene Corp. (CELG: Quote) is scheduled to present interim data from an ongoing phase 2a study of Sotatercept in patients with end stage renal disease on hemodialysis at the National Kidney Foundation 2014 Spring Clinical Meeting. The meeting will take place on April 22-26, 2014.

XLRN closed Monday's trading 6.08% lower at $42.50.

Alphatec Holdings Inc. (ATEC: Quote) said that its consolidated net revenues for full year 2013 rose to $204.7 million from $196.3 million in 2012. Looking ahead to 2014, the company anticipates annual revenues of $208 million to $215 million, representing approximately 1.6% to 5% growth over 2013.

The company also noted that it has settled the OrthoTec vs. Surgiview litigation. Under the terms of the settlement, Alphatec has agreed to pay OrthoTec $49 million over the next 7 years in cash, with an initial cash payment of $17.5 million.

ATEC closed Monday's trading 15.11% higher at $1.60. In after-hours, the stock gained another 4.37% to $1.67.

Amgen Inc. (AMGN: Quote) announced that a phase III trial evaluating its investigational drug Evolocumab has met its primary endpoint of low-density lipoprotein cholesterol reduction in patients with homozygous familial hypercholesterolemia.

In the trial, dubbed TESLA, Evolocumab demonstrated clinically meaningful and statistically significant percent reduction in LDL-C, or "bad" cholesterol from baseline at week 12.

AMGN closed Monday's trading 1.08% higher at $123.86.

Five Prime Therapeutics Inc. (FPRX: Quote) touched a new high of $23.08 on Monday before closing the day's trading at $22.99, following a collaboration deal with Bristol-Myers Squibb Co. (BMY: Quote) to discover novel immuno-oncology therapies for 2 immune checkpoint pathways.

Under the terms of the agreement, Bristol-Myers will obtain exclusive, worldwide rights to develop and commercialize products directed toward certain protein targets identified by Five Prime prior to and during the collaboration. Five Prime will receive an upfront payment of $20 million and up to $9.5 million in research funding over the course of the research term from Bristol-Myers.

More here:
ATEC Sees Growth, FPRX Gets High-Five, RNA Walks The Talk, RPRX On The Move